stockrowCastle Biosciences, Inc. (CSTL) vs Veracyte, Inc. (VCYT)
- Castle Biosciences, Inc. CSTL 32.65 −4.53%
- Veracyte, Inc. VCYT 24.14 +0.58%
Castle Biosciences, Inc. and Veracyte, Inc. are both Diagnostics & Research companies. Veracyte, Inc. is the larger, with a market value of $1.9B against $1.0B — 1.9× the size. Castle Biosciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Veracyte, Inc. trades at 15.2×. Veracyte, Inc. grew revenue faster over the last twelve months: 17.5% against 9.78%. Veracyte, Inc. has the higher net margin (21.8% vs −6.10%) and the higher return on invested capital (4.33% vs −3.63%). Across the 19 metrics below, Veracyte, Inc. leads on 15 and Castle Biosciences, Inc. on 4.
Valuation
Profitability
| Metric | CSTL | VCYT | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 77.07% | 71.98% | 48.32% |
| Operating margin | (7.43%) | 17.08% | (5.68%) |
| Net margin | (6.10%) | 21.80% | (4.10%) |
| Free cash flow margin | 1.06% | 27.84% | 0.00% |
| Return on equity | (4.87%) | 9.43% | 0.00% |
| Return on assets | (4.03%) | 8.63% | (6.05%) |
| Return on invested capital | (3.63%) | 4.33% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack